Correlation Engine 2.0
Clear Search sequence regions

  • adult (1)
  • aspirin (22)
  • asthma (13)
  • blood (2)
  • cohort (1)
  • counts eosinophils (1)
  • eosinophil (3)
  • eosinophilia (1)
  • humans (1)
  • lte4 (1)
  • lung function (1)
  • neutrophil (2)
  • patients (5)
  • protein D (1)
  • serum (2)
  • sputum (1)
  • Sizes of these terms reflect their relevance to your search.

    Aspirin-exacerbated respiratory disease (AERD) is a phenotype of severe asthma, but its disease course has not been well documented compared with that of aspirin-tolerant asthma (ATA). This study aimed to investigate the long-term clinical outcomes between AERD and ATA. AERD patients were identified by the diagnostic code and positive bronchoprovocation test in a real-world database. Longitudinal changes in lung function, blood eosinophil/neutrophil counts, and annual numbers of severe asthma exacerbations (AEx) were compared between the AERD and the ATA groups. Within a year after baseline, two or more severe AEx events indicated severe AERD, whereas less than two AEx events indicated nonsevere AERD. Among asthmatics, 353 had AERD in which 166 and 187 patients had severe and nonsevere AERD, respectively, and 717 had ATA. AERD patients had significantly lower FEV1%, higher blood neutrophil counts, and higher sputum eosinophils (%) (all p < .05) as well as higher levels of urinary LTE4 and serum periostin, and lower levels of serum myeloperoxidase and surfactant protein D (all p < .01) than those with ATA. In a 10-year follow-up, the severe AERD group maintained lower FEV1% with more severe AEs than the nonsevere AERD group. We demonstrated that AERD patients presented poorer long-term clinical outcomes than ATA patients in real-world data analyses. © 2023 John Wiley & Sons Ltd.


    Youngsoo Lee, Chungsoo Kim, Eunyoung Lee, Hyun Young Lee, Seong-Dae Woo, Seng Chan You, Rae Woong Park, Hae-Sim Park. Long-term clinical outcomes of aspirin-exacerbated respiratory disease: Real-world data from an adult asthma cohort. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2023 Sep;53(9):941-950

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 37332228

    View Full Text